Journal of Neural Transmission最新文献

{"title":"Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!","authors":"K Ray Chaudhuri, Karolina Poplawska-Domaszewicz, Indu Subramanian, Wolfgang H Jost","doi":"10.1007/s00702-025-02895-2","DOIUrl":"10.1007/s00702-025-02895-2","url":null,"abstract":"","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"577-580"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of formononetin in chronic unpredictable stress (CUS) linked to parkinson disease.","authors":"Tanvi Dayanand Pingale, Girdhari Lal Gupta","doi":"10.1007/s00702-025-02939-7","DOIUrl":"10.1007/s00702-025-02939-7","url":null,"abstract":"<p><p>Formononetin [FMN] belongs to the member of class 7-hydroxyisoflavones possesses anti-oxidant and anti-inflammatory activity. However, its efficacy in chronic unpredictable stress (CUS) associated with Parkinson disease (PD) is not evaluated. In a current study the effect of FMN on CUS associated with PD was screened to examine efficacy using different behavioral, biochemical and immuno-histochemical evaluation. During the study, CUS associated with PD was induced in mice by administering rotenone followed by exposure to different mild stressors. Animals showing CUS linked to PD were included in the study and treated daily with FMN (5, 10 & 20 mg/kg) by intraperitoneal route. After the treatment, animals evaluated for behavioral, biochemical parameters and immunohistochemistry analysis. Treatment with FMN was effective in alleviating core symptoms of chronic stress linked to PD and improved cognitive function, gait abnormality and impairment in co-ordination of CUS + ROT model. FMN showed dose dependent reduction in IL- 1β, TNF- α, IL- 6 concentration. FMN increasing the levels of dopamine, norepinephrine and serotonin. Immunohistochemical study revealed that the expression of α-synuclein reduced which helps to improve CUS linked to Parkinson's. Furthermore, expression of BDNF and BCL-2 found to be improved after FMN treatment and helps in elevation of dopamine levels thereby surviving neuronal system. Study findings revealed that formononetin is effective in the treatment of chronic unpredictable stress linked to Parkinson's, however further clinical investigation is required to evaluate its effect in human.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"619-633"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-motor fluctuations in Parkinson's disease: frequency and clinical correlate.","authors":"Baig Ilyas Mirza Mujahid, Vikram V Holla, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal, Rohan R Mahale","doi":"10.1007/s00702-025-02908-0","DOIUrl":"10.1007/s00702-025-02908-0","url":null,"abstract":"<p><p>Non-motor symptoms (NMS) occur in 60-97% of Parkinson's disease (PD) patients. NMS show fluctuations over the course of the day referred to as non-motor fluctuations (NMF). To assess the frequency, severity, predictors and effect of the NMF on the quality of life in PD patients. This was a cross-sectional, hospital based, single-centre study. A total of 150 patients with PD were recruited. NMF was assessed using the MDS-Non-motor rating scale (MDS-NMS) and the Non-motor fluctuation assessment questionnaire (NoMoFA). The mean age at presentation and age at onset was 51.3 ± 10.8 years and 44.6 ± 11.1 years respectively and male predominance (75.3%). The mean duration of parkinsonism was 5.3 ± 3.7 years. Motor fluctuations (MF) were seen in 97 patients. A total of 143 patients (95.3%) had at least single NMS. Depression, cognition and pain was the most common NMS domain. NMF was seen in 57 patients (39.8%). NMF occurred in 50.5% in PD patients with MF. Pain was the most frequent NMS which showed NMF followed by fatigue, anxiety and depression. Pain had greater degree of change from ON to OFF period as compared to other NMS domains. NMF was associated with longer disease duration, higher levodopa dose and longer levodopa intake, greater motor severity, MF, higher NMS burden and poor quality of life. NMF is seen in association with MF. Pain, anxiety, depression and fatigue was the common NMS showing NMF. Pain had a large degree of fluctuation in the severity.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"581-588"},"PeriodicalIF":4.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?","authors":"C Buhmann, E Kalbe, I Claus, R Hilker-Roggendorf, T Müller, C W Ip, U Wüllner, R Krüger","doi":"10.1007/s00702-025-02923-1","DOIUrl":"10.1007/s00702-025-02923-1","url":null,"abstract":"<p><p>The demographic development and the advance of intensified yet time and personnel-intensive therapeutic options constitute increasing challenges for the care of people with advanced Parkinson's disease (PD). Often, the multitude of motor and non-motor symptoms cannot be adequately addressed in an ambulatory setting The concept of a Parkinson's day clinic has been put forward to meet the requirements for these patients who not necessarily require the full medical support of an inpatient treatment and was included into the Parkinson's guidelines of the German Neurological Society as a novel and promising medical care model. While the guidelines put forward some recommendations as to which patients are most likely to benefit from treatment in a Parkinson's day clinic, it has not yet been decided which infrastructural, operational, personnel and qualitative requirements such a setting should provide. Here we provide recommendations on the basis of an expert consensus as to which patients will particularly benefit from treatment in a Parkinson´s day clinic and which services such a day clinic should address in order to provide successful therapy. Furthermore we suggest a standard operating procedure (SOP) and we give examples of patients who are suitable for treatment in a Parkinson´s day clinic.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"325-333"},"PeriodicalIF":4.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.","authors":"Thomas Koeglsperger, Emir Berberovic, Christian Dresel, Sebastian Haferkamp, Jan Kassubek, Rahel Müller, Christian Oehlwein, Sebastian Paus, Peter Paul Urban","doi":"10.1007/s00702-025-02911-5","DOIUrl":"10.1007/s00702-025-02911-5","url":null,"abstract":"<p><p>Traditional advanced therapies in Parkinson's disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI's advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"347-359"},"PeriodicalIF":4.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12855247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-occurrence of parkinson disease and multiple sclerosis - a critical note.","authors":"Kurt A Jellinger","doi":"10.1007/s00702-025-02922-2","DOIUrl":"10.1007/s00702-025-02922-2","url":null,"abstract":"<p><p>While multiple sclerosis (MS) is associated with various movement disorders, in particular tremor and ataxia, its combination with parkinsonism is rare and co-occurrence of MS and Parkinson disease (PD) has been reported in only few definite cases. Theories about this co-occurrence range from coincidental to causal, but the true prevalence, basic features and causal relations between the two entities have not been systemically evaluated. Although there are cases of causal relationship between parkinsonism and MS related to demyelinating lesions affecting the dopaminergic nigrostriatal pathway, in a limited number of cases, PD (some gene-mediated) and MS may coexist as two separate diseases in the same patients. The prevalence of MS in LRRK2 PD, while rare, supports an important role for immune function in both disorders, while the role of PD-related PINK is still open. Furthermore, several common genes such as BACE2, CD69, CLC, CPA3 and DEFAs may play important roles in MS and PD, while MS and PD share iron accumulation in substantia nigra, which may be due to protein-protein interaction networks related to metal homeostasis. In view of the various pathogenic possibilities, the causal relationship of concurring MS and PD deserves critical consideration.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"57-63"},"PeriodicalIF":4.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research.","authors":"Ines Novo Pereira, Sara Durão, Haidar Hassan, Ana Cristina Braga, André Mariz Almeida, Ana Cristina Manso, Ricardo Faria-Almeida, Giancarlo De la Torre Canales","doi":"10.1007/s00702-024-02869-w","DOIUrl":"10.1007/s00702-024-02869-w","url":null,"abstract":"<p><p>Botulinum toxin type A (BoNT) has emerged as a potential alternative to conventional therapies to many debilitating chronic diseases characterised by inflammatory states. However, the biological rationale remains ambiguous. Our review aimed to systematically assessed which biochemical biomarkers have been reported in clinical research to evaluate BoNT analgesic and mood-lifting effects in head and neck chronic conditions related to inflammation. We searched databases and registries between inception and September 29, 2023. Of the nine included studies, there were concerns about risk of bias for six studies. The leading biomarker with five studies was the calcitonin gene-related peptide (CGRP), followed by serotonin with two studies. Oxidative stress biomarkers were only reported in one study. Several important players in inflammatory processes and different immune cell classes have been evaluated in four studies. There was only one trial measuring changes in beta Tubulin and SNAP-25, and another study evaluating cutaneous neuropeptide substance-P. After BoNT, a significant effect was reported in six studies, including decrease in plasma levels of CGRP in chronic migraine and trigeminal neuralgia; serotonin decrease when collected from human tears in refractory intractable dry eye disease and increase in peripheral blood platelets in painful cervical dystonia associated to depression and anxiety; decrease in plasma concentration of markers of oxidative damage to proteins and increase in biomarkers for antioxidant power; decrease in expression of gene sets involved in inflammatory pathways and immune cells classes in the periosteum and metalloproteinase-9 molecule in the tears. BoNT seems to affect some biomarkers present in chronic inflammatory conditions. However, the certainty evidence found was very low to moderate. This study is registered on PROSPERO (CRD42023432131).</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"1851-1874"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal botulinum toxin therapy of dystonia in Germany: what would it cost?","authors":"Dirk Dressler, Eckart Altenmüller, Lizhen Pan, Fereshte Adib Saberi","doi":"10.1007/s00702-024-02845-4","DOIUrl":"10.1007/s00702-024-02845-4","url":null,"abstract":"<p><p>Botulinum toxin (BT) therapy is the therapy of choice for most forms of dystonia. We want to describe its costs, if all dystonia patients in Germany would have access to optimal BT therapy. For this, we combined the latest data on epidemiology of dystonia and dosing of BT therapy for dystonia. Missing data were generated for this study. Based on official German pharmacy sales prices, optimal treatment for all dystonia patients in Germany with a population of 84.1 million would generate annual drug costs of €155.5 million (cervical dystonia 89.3, tardive dystonia 22.1, generalised dystonia 17.9, blepharospasm 9.3, segmental dystonia 5.9, writer's cramp 5.3, arm dystonia 3.2, oromandibular dystonia 2.3, musician's dystonia 0.3, spasmodic dysphonia 0.1) This is €1.85 annually per capita or 0.3% of the total 2021 drug budget and 42% of the 2021 Parkinson drug budget of German public insurance companies. Actual costs for the health care system are considerably lower, as there are various discounts to consider. Further reductions would be possible. BT therapy's individual costs are high. Its costs for the health care system, however, are marginal. Comparing projected and actual costs, would allow estimating availability and quality of BT therapy of dystonia in Germany.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"1875-1879"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antinociceptive properties of intravesical/needle-free administration of abobotulinumtoxinA in a rodent model of chronic visceral pain: in vivo and histological evidence.","authors":"Céline Augé, Mathieu Vogt, Vincent Martin, Stéphane Lezmi, Xavier Gamé, Philippe Lluel, Jacquie Maignel","doi":"10.1007/s00702-025-02906-2","DOIUrl":"10.1007/s00702-025-02906-2","url":null,"abstract":"<p><p>While interstitial cystitis along with bladder pain syndrome (IC/BPS) is still poorly treated, published clinical evidence suggests that onabotulinumtoxinA (natural botulinum neurotoxin type A (BoNT/A)) intradetrusor injections is efficient in IC/BPS. However, as bladder instillation could be a safer and more convenient administration route, we aimed to investigate the effect of BoNT/A needle-free administration in an IC/BPS rodent model. Cyclophosphamide (CYP) was used to induce IC/BPS in rats. The resulting symptoms mimicked the main key features of human non-ulcerative IC/BPS. AbobotulinumtoxinA (aboBoNT-A) or reference compounds used in the clinic were delivered as a single intravesical administration into the bladder via the urethra. Visceral allodynia and hyperalgesia were assessed at the abdominal level with von Frey filaments before and after bladder pain induction. The levels of BoNT/A-cleaved SNAP25 (c-SNAP25), total SNAP25 (SNAP25^N-ter), beta-3 tubulin and CGRP in bladders were also quantified using immunohistochemistry (IHC), as well as the histopathological lesions. AboBoNT-A was well tolerated up to 30 U/rat. Allodynia and hyperalgesia were significantly decreased after aboBoNT-A dosing, with higher efficacy compared to references. c-SNAP25 IHC levels were low and similar in the detrusor for the 3 aboBoNT-A groups. Neither CYP or aboBoNT-A induced any change in the amount of SNAP25, beta-3 tubulin or CGRP. Some CYP-induced histopathological lesions showed a trend in improvement under aboBoNT-A. AboBoNT-A displayed analgesic properties that could translate into better therapies for visceral pain. Interestingly, intravesical (needle-free) administration seems like a promising and reproducible route for botulinum toxin therapy in patients with IC/BPS.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"1765-1777"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An orthogonal approach for analysis of underivatized steroid hormones using ultrahigh performance supercritical fluid chromatography-mass spectrometry (UHPSFC-MS).","authors":"Perry Devo, Victoria Cretu, Harsha Radhakrishnan, Darren Hamilton-Pink, Stergios Boussios, Saak V Ovsepian","doi":"10.1007/s00702-024-02862-3","DOIUrl":"10.1007/s00702-024-02862-3","url":null,"abstract":"<p><p>The crucial role of steroid hormones in health and diseases merits their high-throughput, accurate and affordable measurements in biological specimens. Despite advances in analytical methods, sensing and quantifying steroid hormones remains challenging. Immunoassays offer excellent sensitivity but are inherently labour-intensive, costly, and prone to false positives. Mass spectrometry (MS) has been increasingly utilised, with the main hurdle being the isobaric tendencies of similar analytes, which complicates their separation and accurate quantification. This study compares ultrahigh-performance supercritical fluid chromatography separation (UHPSFC) and ultra-high-performance liquid chromatography (UHPLC) for MS detection. It optimises the column chemistry, temperature, and pressure to provide an operational protocol for the resolution and quantification of analytes. It presents the systematic characterisation of UHPSFC-MS performance by investigating spiked blood samples using Solid-Phase Extraction (SPE) and describes the matrix effects associated with MS measurements. Although both separation methods showed adequate resolution, specificity, and retention time, UHPSFC-MS was superior for five out of seven columns tested. With added high-throughput capacities, UHPSFC-MS, thus, offers an optimal solution for the analysis of steroid hormones for research, medical chemistry, and clinical diagnostics.</p>","PeriodicalId":16579,"journal":{"name":"Journal of Neural Transmission","volume":" ","pages":"1815-1823"},"PeriodicalIF":4.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}